ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 65 filers reported holding ASCENDIS PHARMA A/S in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $572,340,627 | -4.6% | 4,196,661 | +5.8% | 7.62% | +9.0% |
Q1 2024 | $599,640,899 | +26.8% | 3,966,666 | +5.6% | 6.99% | +7.0% |
Q4 2023 | $473,012,152 | +37.6% | 3,755,555 | +2.3% | 6.53% | +21.9% |
Q3 2023 | $343,658,800 | +7.5% | 3,670,000 | +2.5% | 5.36% | +23.6% |
Q2 2023 | $319,564,534 | -10.4% | 3,580,555 | +7.7% | 4.34% | -18.0% |
Q1 2023 | $356,506,500 | -5.8% | 3,325,000 | +7.3% | 5.28% | -6.6% |
Q4 2022 | $378,603,000 | +28.6% | 3,100,000 | +8.8% | 5.66% | +4.1% |
Q3 2022 | $294,291,000 | +39.2% | 2,850,000 | +25.3% | 5.44% | +30.1% |
Q2 2022 | $211,484,000 | -18.1% | 2,275,000 | +3.4% | 4.18% | -11.3% |
Q1 2022 | $258,192,000 | -4.0% | 2,200,000 | +10.0% | 4.71% | +2.9% |
Q4 2021 | $269,060,000 | -14.7% | 2,000,000 | +1.0% | 4.58% | -7.6% |
Q3 2021 | $315,592,000 | +26.3% | 1,980,000 | +4.2% | 4.96% | +14.0% |
Q2 2021 | $249,945,000 | -16.7% | 1,900,000 | +5.6% | 4.35% | -15.9% |
Q4 2020 | $300,204,000 | +8.1% | 1,800,000 | 0.0% | 5.17% | +31.0% |
Q3 2020 | $277,776,000 | +7.3% | 1,800,000 | +2.9% | 3.95% | -22.9% |
Q2 2020 | $258,825,000 | +28.6% | 1,750,000 | -2.1% | 5.12% | -24.7% |
Q1 2020 | $201,234,000 | -22.4% | 1,787,000 | -4.2% | 6.79% | -10.8% |
Q4 2019 | $259,459,000 | +36.7% | 1,865,000 | -5.3% | 7.62% | -3.8% |
Q3 2019 | $189,750,000 | -16.4% | 1,970,000 | 0.0% | 7.92% | +0.9% |
Q2 2019 | $226,846,000 | +7.4% | 1,970,000 | +9.7% | 7.84% | -14.2% |
Q1 2019 | $211,272,000 | +70.3% | 1,795,000 | -9.3% | 9.14% | +23.2% |
Q4 2018 | $124,047,000 | -10.8% | 1,980,000 | +0.8% | 7.42% | +16.1% |
Q3 2018 | $139,122,000 | +1.4% | 1,963,336 | -4.8% | 6.39% | +20.9% |
Q2 2018 | $137,253,000 | +1.7% | 2,063,336 | 0.0% | 5.28% | -18.0% |
Q1 2018 | $134,942,000 | +100.4% | 2,063,336 | +22.7% | 6.44% | +47.6% |
Q4 2017 | $67,342,000 | +13.5% | 1,681,024 | +2.7% | 4.36% | -5.1% |
Q3 2017 | $59,309,000 | +115.6% | 1,636,124 | +65.1% | 4.60% | +32.5% |
Q2 2017 | $27,508,000 | +40.2% | 990,924 | +41.4% | 3.47% | +38.5% |
Q1 2017 | $19,626,000 | +77.9% | 700,924 | +28.6% | 2.51% | +12.5% |
Q4 2016 | $11,035,000 | +1114.0% | 545,203 | +1106.1% | 2.23% | +1301.9% |
Q3 2016 | $909,000 | – | 45,203 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |